Nexletol shows CLEAR benefit in cardiovascular outcome trial New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . . ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
Therapeutic Value of SGLT2 Inhibitors in the Management of . . . SGLT2 inhibitors have transformed the treatment of cardiovascular disease, providing substantial therapeutic promise for a wide range of patients They are anticipated to become more and more important in the prevention and management of cardiovascular disease
THE HEART-CANCER CONNECTION: EXPLORING SGLT2 INHIBITORS . . . THE HEART-CANCER CONNECTION: EXPLORING SGLT2 INHIBITORS’ CARDIOVASCULAR ADVANTAGES Authors: Aravind Dilli Babu, Abdelrahman Ali, Sahib Singh, Jayanth Reddy Tallapalli, Ruchita Jadhav, Chiranjeevi Sainatham, Syed Ishaq, Zurain Niaz, Bijay Mukesh Jeswani, and Paul A Gurbel Authors Info Affiliations Publication: JACC Volume 85, Number 12
FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to . . . Esperion announced that the FDA approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . . U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores . . . Abstract Background: Cardiovascular disease (CVD) is a leading cause of mortality in Type 2 diabetes mellitus (T2DM) Sodium-glucose co-transporter 2 (SGLT2) inhibitors are known to provide cardioprotective effects, but their influence on validated cardiovascular risk models remains underexplored